CEBPB is associated with active tumor immune environment and favorable prognosis of metastatic skin cutaneous melanoma

Front Immunol. 2022 Oct 24:13:991797. doi: 10.3389/fimmu.2022.991797. eCollection 2022.

Abstract

Metastatic skin cutaneous melanoma (SKCM) is a common malignancy that accounts for low morbidity but high mortality of skin cancer. SKCM is characterized by high lymphocytic infiltration, whereas the states of infiltrated cells are variable in patients leading to a heterogeneous prognosis and hindering appropriate clinical decisions. It is therefore urgent to identify markers associated with lymphocytic infiltration, cellular conditions, and the prognosis of SKCM. In this study, we report that CEBPB, a transcriptional factor, is mainly expressed in macrophages in metastatic SKCM and associated with an active tumor immune environment and a favorable prognosis through integrated analysis of single-cell and bulk RNA-seq datasets. High CEBPB expression is significantly associated with active inflammation and immune response pathways in both macrophages and bulk SKCM tumor tissues. A signature based on CEBPB-associated genes that are specifically expressed in macrophages could robustly and prognostically separate different metastatic SKCM patients. In addition, the associations between the metastatic SKCM tumor signature and microenvironment with respect to T-cell recruitment and state, inflammation response, angiogenesis, and so on were also determined. In conclusion, we present here the first report on CEBPB in tumor immune environment and prognosis regulation in metastatic SKCM and construct a reliable signature, which should provide a useful biomarker for stratification of the patient's prognosis and therapeutic selection.

Keywords: CEBPb; SKCM; immune subtype; single cell RNAseq; tumor immune microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • CCAAT-Enhancer-Binding Protein-beta / genetics
  • Humans
  • Inflammation
  • Melanoma* / pathology
  • Melanoma, Cutaneous Malignant
  • Neoplasms, Second Primary*
  • Prognosis
  • Skin Neoplasms* / pathology
  • Tumor Microenvironment

Substances

  • Biomarkers
  • CEBPB protein, human
  • CCAAT-Enhancer-Binding Protein-beta